< Back to previous page

Publication

The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer

Journal Contribution - Journal Article

Dendritic cell (DC) mono-immunotherapy has not been successful so far in ovarian cancer. The addition of a toll-like receptor (TLR) agonist has the potential to boost the innate immune system, in addition to the adoptive immune response initiated by DCs.
Journal: ANTICANCER RESEARCH
ISSN: 0250-7005
Issue: 11
Volume: 36
Pages: 5781 - 5792
Publication year:2016
BOF-keylabel:yes
IOF-keylabel:yes
BOF-publication weight:0.1
CSS-citation score:1
Authors from:Higher Education
Accessibility:Open